Analysts anticipate presentation of Avastin data

New data on the use of Roche's Avastin in ovarian cancer patients is due at next week's European Society for Medical Oncology meeting; after the company's recent announcement that the drug proved effective against the disease, analysts are anxious to see the details so they can estimate sales accurately. Report